MAHIA, New Zealand, Oct. 23, 2026 (GLOBE NEWSWIRE) — Rocket Lab Corporation (Nasdaq: RKLB), a global leader in launch services and space systems, today launched its Electron rocket to deliver a dedicated mission to space for HawkEye 360, a signals intelligence data and analytics company. The ‘We’re Not Hawking Around’ mission launched from Rocket Lab Launch Complex 1 in New Zealand at 8:11 p.m. NZDT on 23 October 2026, to deliver three HAWK satellites to a 520km low Earth orbit. Operating in tri-satellite formation, HawkEye 360’s satellites collect signal data from across the radio frequency (RF) spectrum for maritime tracking, GNSS jamming detection, radar monitoring, communications mapping, and space defense. Today’s mission was Rocket Lab’s 98th Electron launch and 19th launch this year, further extending the vehicle’s...

Hydro’s adjusted EBITDA for the third quarter of 2026 was NOK 9,089 million, up from NOK 5,996 million in the same quarter last year. Higher all-in metal prices and higher alumina prices contributed positively in the quarter, along with improved earnings in Recycling and Extrusions. The strong performance was partially offset by higher anode and energy costs in Aluminium Metal, increased energy costs in Bauxite & Alumina due to gas supply disruptions, a stronger NOK vs USD, and negative price area differences in Energy.Alunorte resumed regular operations following temporary gas supply disruptions Free cash flow of NOK 1.4 billion impacted by higher metal prices and associated working capital requirements and prepaymentsFirst metal produced at HalZero test facility, marking important milestone for carbon-free technology trackCommercial...

SHANGHAI, China, Oct. 23, 2026 (GLOBE NEWSWIRE) — On October 21, Professor Joseph Sifakis, a Turing Award laureate and Chief Scientific Advisor of the CaoCao Mobility AI Innovation Research Center, visited the center for in-depth discussions with CaoCao’s technology team. On the same day, CaoCao launched a research project on Trustworthy Decision-Making and Multi-Agent Coordination for Robotaxi Curbside Operations. Professor Sifakis witnessed the launch and offered valuable recommendations based on his extensive research experience.Professor Sifakis is one of the pioneers of model checking. He received the 2007 Turing Award for his contributions to the development of model-checking theory and its applications. He has long been engaged in research on complex intelligent systems and Trustworthy Autonomous Systems, areas closely...

In a 1L EGFR atypical population with more than double the rate of baseline CNS metastases as competitor datasets, enozertinib demonstrates a potential best-in-class 84% confirmed systemic ORR and 70% confirmed intracranial ORR, with multiple intracranial complete responses 88% 6-month landmark PFS compares favorably to current standards of care and to investigational therapies; follow-up ongoing with majority of patients continuing on treatment Competitive safety profile with no significant off-target toxicity and no treatment-related discontinuations Redwood-1 global Phase 3 registrational trial initiation in 1L EGFR atypical NSCLC expected in 1H 2027 Company to host a conference call and webcast today at 8:00 am ET featuring Dr. Joshua Sabari SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Oct. 23, 2026 (GLOBE NEWSWIRE) — ORIC Pharmaceuticals,...

Preclinical data highlight potential advantages of targeting PRC2 via EED over EZH2, including the emergence of resistance mutations to EZH2 inhibitors like mevrometostat and against which the EED inhibitor rinzimetostat maintained effectiveness Preclinical results, supported by translational data in mCRPC patient samples, show rinzimetostat reinforces a luminal, AR-dependent state, restricts lineage plasticity and enhances sensitivity to AR inhibition Findings reinforce rinzimetostat’s differentiated profile and support development across the prostate cancer disease spectrum, including in the ongoing Himalayas-1 Phase 3 trial SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Oct. 23, 2026 (GLOBE NEWSWIRE) — ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing and commercializing treatments...

The shareholders are invited to attend the general meeting of Econocom Group SE, with registered office at Place du Champ de Mars 5, 1050 Brussels, Belgium, registered with the Crossroads Bank for Enterprises under number 0422.646.816 (the “Company“), to be held on Tuesday 24 November 2026 at 2 p.m. (Belgian time) at the Company’s registered office (the “Meeting“). AGENDA AND PROPOSED RESOLUTIONS FOR THE GENERAL MEETINGAppointment of Ms. Véronique Torner as independent directorProposed resolution:Proposal to appoint Ms. Véronique Torner as independent director of the Company for a term of 4 (four) years, with immediate effect and ending at the close of the annual general meeting to be held in 2030. Ms. Véronique Torner meets the independence criteria set out in Article 7:87 of the Code on companies and...